Hemanext Diagnostic Technologies
The inability of stored RBCs to reach capillaries as effectively as their fresh
counterparts is one of the possible causes of increased morbidity and mortality
often associated with transfusion therapy.
The Hemanext Diagnostic Technologies are comprised of two simple-to-use, disposable
devices designed for point-of-care assessment of stored red blood cells (RBCs) ability
to perfuse microvascular networks.
Human Erythrocyte Microchannel Analyzer (HEMA)
The first diagnostic device, HEMA, precisely measures the surface area and volume
of individual RBCs.
Hemanext Microchannel Network (MCN)
The MCN tests RBCs ability to perfuse capillaries by measuring how well the RBCs
perfuse an artificial microvascular network. The device will be inexpensive and
easy to operate, and will thus enable routine testing of the microvascular fitness
of stored RBCs in every unit of blood intended for transfusion. A quantitative assessment
of the quality of stored blood will help physicians to evaluate the risks and benefits
of transfusing every specific unit, and therefore could improve the overall efficacy
of transfusion therapy and reduce the potential complications associated with the
transfusion of bad blood.
